|
|
|
| Webinar: CRISPR meets LNPs: A new era in cell and gene therapies | Join industry experts as they present new data demonstrating the potential of CRISPR-LNPs for multiplex gene editing in primary human T cells. Explore how non-viral delivery platforms like LNPs could reshape the future of cell and gene therapy—from manufacturing and regulation to clinical translation. Click here to learn more. |
|
|
|
|
Shifting demand for oligos and peptides drove innovation in CDMO partnerships and reshaped outsourcing relationships. In this Outsourced Pharma Live panel, industry experts shared best practices for outsourcing these specialized therapeutics, with a focus on capacity, regulatory challenges, and technology transfer. |
|
|
|
By M. Tobolowsky and M. Schwartz, Hyman, Phelps & McNamara | The FDA's new Advanced Manufacturing Technology program has its first recipient, a development expected to reveal the specific ways the program benefits drug innovators. | |
|
|
|
By AR Welch, Editorial & Community Director, Advancing RNA | During the panel discussion last November, three CDMO execs shared the biggest scientific, regulatory, and technological complexities barring a “magical” solution to each biotech’s wishes. | |
|
|
|
| Optimize Your RNA-LNP Delivery With Ionizable Lipids | Video | Cytiva | Ionizable lipids play a crucial role in optimizing LNP delivery. Discover how lipid nanoparticles revolutionize intracellular drug delivery to enhance RNA vaccines, cell therapies, protein replacement, and gene editing. |
|
|
|
| 5 Trends Impacting CMOs In 2025 | Article | Jubilant HollisterStier | In 2025, CMOs will navigate Annex 1 compliance, the BioSecure Act’s uncertainty, AI-driven drug development, supply chain challenges from tariffs, and pandemic preparedness strategies. |
|
|
|
|
| CQA Assessment Of LNP-Encapsulated IVT mRNA | Application Note | Agilent Technologies | Learn about issued guidelines on Critical Quality Attributes for IVT mRNA vaccines and biotherapeutics to focus on drug substance and LNP-encapsulated drug product assessment using an analyzer system. |
|
|
| Demystifying CRISPR gRNA Chemical Modifications | Article | By R. Roberts, Ph.D., K. Holden, Ph.D., and A. Zepeda, Synthego Corporation | Chemical modifications on CRISPR gRNAs enhance stability, editing efficiency, and reduce immune responses, enabling in vivo applications and clinical success. |
|
|
|
|
|
|
|
| Delivery remains RNA therapeutics' biggest hurdle—especially beyond the liver. In this Advancing RNA Live, Anna Rose Welch is joined by experts exploring nonviral, non-LNP delivery solutions pushing the boundaries of coding and noncoding RNA. Hear what makes these novel vehicles promising and learn how companies are tackling the scientific and operational challenges that stand in the way. Don’t miss this deep dive into the future of RNA drug delivery innovation. |
|
|
.png){kind=logo}
